Laboratorios RichmondC.I.F Valuation

Is RICHD undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RICHD when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RICHD's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RICHD's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RICHD?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for RICHD. This is calculated by dividing RICHD's market cap by their current preferred multiple.
What is RICHD's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	AR$73.97b

RICHD key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	5.2x
Enterprise Value/EBITDA	24.5x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does RICHD's PE Ratio compare to its peers?

The above table shows the PE ratio for RICHD vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	22.3x
ROSE Instituto Rosenbusch	4.2x	n/a	AR$4.2b
UMED Unité de Fabrication des Médicaments	36.1x	60.7%	د.ت232.0m
DCL Cuu Long Pharmaceutical	29.4x	n/a	₫1.9t
ACCENTMIC Accent Microcell	19.6x	n/a	₹5.9b
RICHD Laboratorios RichmondC.I.F	20.8x	n/a	US$74.0b

Price-To-Earnings vs Peers: RICHD is good value based on its Price-To-Earnings Ratio (20.8x) compared to the peer average (22.3x).

Price to Earnings Ratio vs Industry

How does RICHD's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	19.4%
	n/a	n/a	n/a

No more companies

Price-To-Earnings vs Industry: RICHD is good value based on its Price-To-Earnings Ratio (20.8x) compared to the Global Pharmaceuticals industry average (24.7x).

Price to Earnings Ratio vs Fair Ratio

What is RICHD's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RICHD PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	20.8x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate RICHD's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.